Effectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, India
| Autor: | Siju Seena, Gaurab Mitra, Krishna Pandey, Jitendra Gupta, Pedro Pablo Palma, N. Kumar, Vidya Nand Rabi Das, Manica Balasegaram, Prabhat K. Sinha, Fernando Parreño, María Angeles Lima, Jean-François Saint-Sauveur, Paul Roddy, Alice Kociejowski |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.drug_class Antibiotics Antiprotozoal Agents India Body weight Cohort Studies Young Adult Pharmacotherapy Amphotericin B Virology Internal medicine medicine Humans Child Adverse effect business.industry Leishmaniasis Articles Middle Aged medicine.disease Surgery Infectious Diseases Visceral leishmaniasis Child Preschool Liposomes Leishmaniasis Visceral Female Parasitology Liposomal amphotericin business medicine.drug |
| Zdroj: | The American Journal of Tropical Medicine and Hygiene. 83:357-364 |
| ISSN: | 1476-1645 0002-9637 |
| DOI: | 10.4269/ajtmh.2010.10-0156 |
| Popis: | We evaluated, through the prospective monitoring of 251 patients at Sadar Hospital in Bihar, India, the effectiveness and safety of 20 mg/kg body weight of liposomal amphotericin B for the treatment of visceral leishmaniasis. The treatment success rates for the intention-to-treat, per protocol, and intention-to-treat worse-case scenario analyses were 98.8%, 99.6%, and 81.3%, respectively. Nearly one-half of patients experienced mild adverse events, but only 1% developed serious but non-life-threatening lips swelling. The lost to follow-up rate was 17.5%. Our findings indicate that the 20 mg/kg body weight treatment dosage is effective and safe under routine program conditions. Given that the exor- bitant cost of liposomal amphotericin B is a barrier to its widespread use, we recommend further study to monitor and evaluate a lowered dosage and a shorter treatment course. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|